Healthcare >> Analyst Interviews >> July 18, 2012

Chinese Medical Research and Biotech Companies Set to Outpace Western Peers

Yin, Ingrid
Ingrid Yin covers China health care as a Managing Director and Senior Analyst for Oppenheimer &. Co. Inc. She joined Oppenheimer from Brean Murray Carret & Co., where she was the Senior Analyst for China health care since 2009. Before her work at Brean Murray, she was an Asian Equity Analyst at Wellington Management. Dr. Yin also has held positions at Jefferies Asset Management and Sirios Capital Management. Before moving to Wall Street, Dr. Yin was a Senior Research Scientist at Memorial Sloan-Kettering Cancer Center in New York. She holds an MBA from the Massachusetts Institute of Technology Sloan School of Management, a Ph.D. in biochemistry from The State University of New York-Stony Brook and a B.S. in chemistry from Peking University. Profile
TWST: Would you give us an overview of the medical research service and biotech industry in China? You’ve described other areas of health care as rapidly growing.

Dr. Yin: These